BioLife Solutions has executed a successful turnaround by refocusing on core products and divesting non-core assets. Read ...

Good afternoon, and thank you for joining us for BioLife Solutions, Inc.'s fourth quarter and full year 2025 conference call.

Goldman Sachs (GS) has been on a downward spiral lately with significant selling pressure. After declining 12.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is ...

Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions, Inc. Q4 2025 ...

BioLife Solutions Inc. reports fourth-quarter 2025 earnings after market close Thursday, with investors scrutinizing whether the biopreservation specialist can maintain momentum after a strong third ...

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.01 per share a year ...

BOTHELL, Wash., Feb. 17, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") ...

MEGA BiO-LiFE Malaysia was named Natural Health Iconic Brand 2025 at the Natural Health & 健康时尚 Readers’ Choice ...

Management issued 2026 guidance for total revenue between $112 million and $115 million, representing growth of 17% to 20%. de Greef said, "we see continued operating and adjusted EBITDA margin ...

The MarketWatch News Department was not involved in the creation of this content. BOTHELL, Wash., Feb. 17, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier ...

Total Revenue (Q4 2025): $24.8 million, a 20% increase year-over-year. Total Revenue (Full Year 2025): $96.2 million, a 29% increase year-over-year. Adjusted Gross Margin (Q4 2025): $15.8 million or ...